MetaCap

Perspective Therapeutics (CATX) vs Cumberland Pharmaceuticals (CPIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cumberland Pharmaceuticals (CPIX) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 193.5% versus a loss of 63.9%. Over five years, CPIX leads with a +161.9% price change compared with -84.6% for CATX. Perspective Therapeutics is the larger company by market cap ($91.0 million vs $87.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CATX-63.93%CPIX+193.47%
+371%+143%-85%
Nov 21, 20251 yearNov 20, 2026
CATX-84.62%CPIX+134.54%
+287%+92%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CATX versus CPIX key metrics
MetricCATXCPIX
Share price$0.7538$5.84
Market cap$91.03M$87.57M
1-day change-3.85%-7.30%
YTD return-72.59%+46.73%
1-year return-63.93%+193.47%
5-year return-84.62%+161.88%
Forward P/E—41.71
EPS (TTM)$-1.25$-0.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$44.52M
Revenue growth (YoY)—+17.57%
Net income (latest FY)$-103.12M$-2.84M
Gross margin—85.02%
Operating margin—-6.27%
Net margin—-6.37%
52-week high$6.16$9.28
52-week low$0.73$2.00
Distance from 52-week high-87.76%-37.07%
Analyst consensusstrong_buy—
Avg. price target upside+1188.14%—
Average volume2.70M114.52K
Shares outstanding120.76M15.00M
Employees16388
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CPIX has outperformed CATX by 257.4 percentage points over the past year.

About Perspective Therapeutics

CATX stock →

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees

About Cumberland Pharmaceuticals

CPIX stock →

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.

Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees

CATX vs CPIX FAQ

Which is bigger, Perspective Therapeutics or Cumberland Pharmaceuticals?

Perspective Therapeutics (CATX) is larger, with a market capitalization of $91.03M compared with $87.57M for Cumberland Pharmaceuticals (CPIX).

Which stock has performed better over the past year, CATX or CPIX?

CPIX returned +193.47% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.

Are Perspective Therapeutics and Cumberland Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons